Home MicroPort Scientific Corporation

MicroPort Scientific Corporation

MicroPort®’s Firehawk® Drug Eluting Stent Achieves Primary Endpoint and Shows Very Promising Results From TARGET All-Comers Clinical Trial

5/23/18: "Data from the TARGET AC trial, which included the most complex patient real world population in Europe, demonstrated exceptional performance and safety of the Firehawk® stent," said William Wijns, M.D., PhD, National University of Ireland Galway, Ireland, and principal investigator for the study. "With this European clinical data set, Firehawk® has the potential to positively impact patient care by further reducing the risk of late adverse events and the need for device-mandated prolonged dual antiplatelet therapy, which is often associated with a higher risk of bleeding as well as increased patient treatment cost."

Lombard Medical and MicroPort Scientific Corporation Finalize Strategic Partnership Agreements

Lombard Medical and MicroPort Scientific Corporation Finalize Strategic Partnership Agreements Aorfix™, the only stent graft to hold global...